EGFR and HER2 expression predict outcome of muscle-invading bladder cancers
This article has no abstract so we have provided the first paragraph of the full text.
Elevated expression of the epidermal growth factor receptor (EGFR) and related family member HER2 is associated with adverse outcome in many tumor types, and data from pre-clinical and clinical trials have shown a therapeutic benefit from blocking the activity of these proteins. Increasing activity of EGFR family members mediates antiapoptotic and proinvasive effects, and there is growing evidence suggesting the involvement of these proteins in tumor-cell resistance to cytotoxic agents.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.